Imaging of Solid Tumors Using DLL3 SPECT

Launched by THOMAS HOPE · Jun 28, 2025

Keywords

ClinConnect Summary

This clinical trial is testing a new type of imaging scan to help find and see cancer that has spread in the body. The scan uses a special substance called 111In-ABD147, which targets a protein called DLL3 found on certain tumors, especially those with neuroendocrine features—a type of cancer cell that behaves differently than most. This trial aims to see how well this new scan can detect tumors in people with solid cancers, including prostate cancer that no longer responds to hormone therapy and certain aggressive neuroendocrine tumors.

People who might take part are adults (18 years and older) who have solid tumors that have spread to other parts of the body. The study is divided into three groups: those with advanced prostate cancer resistant to hormone treatment, those with high-grade neuroendocrine tumors, and a group open to other types of solid tumors. Participants will undergo this new imaging scan to help doctors see where the cancer is located. The trial is currently not recruiting but is designed for both men and women who can understand and agree to the study’s requirements. It’s important to know that people who have severe allergies to similar treatments or are pregnant will not be eligible. This study could help improve how doctors detect and monitor certain cancers in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥ 18 years
• 2. Histopathologically confirmed solid tumors in one of the following cohorts:
• • 1. Cohort 1 (n=15): Histologically confirmed prostate cancer, with castration resistant disease per Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria.
• • 2. Cohort 2 (n=15): Histologically confirmed high grade neuroendocrine tumor, with a Ki-67 over 20.
• • 3. Cohort 3 (n=15): Agnostic to tumor type.
• • 3. Metastatic disease present on conventional imaging defined as having Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 measurable disease or multiple bone metastases.
• • 4. Ability to understand a written informed consent document, and the willingness to sign it.
• Exclusion Criteria:
• • 1. Unlikely to comply with protocol procedures, restrictions and requirements and judged by the Investigator to be unsuitable for participation.
• • 2. Has known hypersensitivity to Chinese hamster ovary cell products.
• • 3. Has a history of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins.
• • 4. Known pregnancy.